证券日报网讯宏力达11月14日在互动平台回答投资者提问时表示，公司核心技术产品智能柱上开关通过 与传统电气开关、物联传感设备、边缘计算和工业控制设备的融合，不仅提升了故障研判、定位和隔离 的效率，还实现了远程人机交互，获得用户的高度认可。公司基于产品长期运行的现场特征数据持续进 行创新研发，优化产品研发设计，改进故障研判数据算法，开发新的故障研判模型，提高故障研判准确 率和故障处置速度。 （文章来源：证券日报） ...

一、说明会类型 会议问题征集：投资者可于 2025 年 11 月 20 日下午 17:00 前访问网址 https://eseb.cn/1tc4B4ia4yA 或扫描下方小程序码点击"互动交流"，进行会前提问， 公司将通过本次业绩说明会，在信息披露允许范围内就投资者普遍关注的问题进 行回答。 关于举办 2025 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 证券代码：688330 证券简称：宏力达 公告编号：2025-043 上海宏力达信息技术股份有限公司 二、说明会召开的时间、地点和方式 会议召开时间：2025 年 11 月 21 日（星期五）15:30-16:30 会议召开地点：价值在线（www.ir-online.cn） 会议召开方式：网络文字互动 三、参加人员 出席公司本次业绩说明会的有：董事长章辉先生，董事、总经理冷春田先生， 独立董事文东华先生，财务总监张占先生，董事会秘书宫文静女士（如有特殊情 况，参会人员将可能调整）。 四、投资者参加方式 投 资 者 可 于 ： ...

每经AI快讯，有投资者在投资者互动平台提问：请董秘及时介绍公司参股的太空电源公司馥昶空间本 轮融资的估值情况，并介绍本轮投后宏力达持股比例是多少？ （记者 王瀚黎） 宏力达（688330.SH）11月14日在投资者互动平台表示，公司通过专项基金参投苏州馥昶空间技术有限 公司，间接持股比例较低，且未参与馥昶空间的日常经营管理，馥昶空间的具体情况请您关注其公开信 息。 ...

Group 1 - The core viewpoint of the article highlights the growth in the electrical machinery and equipment manufacturing industry in China, with a notable increase in export value [1] - In September 2025, the export value of the electrical machinery and equipment manufacturing industry reached 150.53 billion yuan, representing a year-on-year growth of 7% [1] - From January to September 2025, the cumulative export value was 1,333.73 billion yuan, with a year-on-year increase of 6.4% [1] Group 2 - The article lists several publicly listed companies in the electrical machinery sector, including XJ Electric, Dongfang Electronics, and Jinzhiketech, among others [1] - The data presented is sourced from the National Bureau of Statistics and compiled by Zhiyan Consulting, indicating a robust market outlook for the industry [1] - Zhiyan Consulting is recognized as a leading industry consulting firm in China, providing comprehensive industry research reports and consulting services [1]

Investment Rating - The investment rating for the pharmaceutical and biotechnology industry is "Positive" and the rating has been maintained [1] Core Views - The investment logic in the pharmaceutical sector is shifting from policy pressure to innovation-driven growth, with the "14th Five-Year Plan" directly supporting the development of innovative drugs and medical devices [8][26] - The industry is witnessing a transition from rapid following to original innovation, as demonstrated by Chinese companies showcasing their global competitiveness and pipeline value at the 2025 ESMO conference [8][26] - The recent approval of innovative drugs and the successful listing of companies on the STAR Market indicate a supportive capital market for innovative pharmaceutical enterprises [8][26] Industry Review - The pharmaceutical and biotechnology industry index increased by 1.89%, ranking 20th among 31 primary industries, underperforming the CSI 300 index which rose by 2.80% [5][16] - The sub-industries of medical research outsourcing and vaccines showed the highest gains, with increases of 5.26% and 4.19% respectively, while medical devices and traditional Chinese medicine experienced declines of 1.21% and 0.56% [5][16] - As of October 31, 2025, the industry’s PE (TTM, excluding negative values) was 30.67x, up from 30.08x in the previous period, indicating an upward valuation trend but still below the average [21] Company Dynamics - A total of 36 listed companies in the pharmaceutical and biotechnology sector experienced a net reduction in shareholder holdings amounting to 805 million yuan, with 4 companies increasing holdings by 120 million yuan and 32 companies reducing holdings by 925 million yuan [5][6] - Among the 501 tracked companies, 499 have disclosed their performance for the first three quarters of 2025, with 53 companies reporting a net profit growth of 100% or more, and 69 companies reporting growth between 30% and 100% [6] Investment Recommendations - Focus on companies with strong positions in innovative drugs and cutting-edge technology platforms, particularly those involved in ADC, bispecific/multispecific antibodies, and cell therapy, which can provide high potential for international market expansion [8] - Pay attention to the CXO industry, which is expected to see increased demand due to the recovery of innovative drug development and commercialization, especially for leading companies with strong service capabilities in new technology areas [8]

Core Viewpoint - Honglida (688330.SH) reported its Q3 2025 results, highlighting a significant presence of institutional investors holding 40.35% of its total shares, although this represents a slight decrease from the previous quarter [1] Group 1: Institutional Investors - As of October 30, 2025, five institutional investors disclosed their holdings in Honglida A-shares, totaling 56.4851 million shares [1] - The total shareholding by institutional investors decreased by 0.52 percentage points compared to the previous quarter [1] - The institutional investors include Shanghai Hongyuan Investment Group Co., Ltd., Shanghai Yuehai Investment Center (Limited Partnership), Shanghai Hongyuan Contract Energy Management Center (Limited Partnership), Beijing Yueyunshan Enterprise Management Co., Ltd., and Shanghai Pinhua Investment Consulting Co., Ltd. [1] Group 2: Public Funds - In this reporting period, 48 public funds were disclosed, which were not reported in the previous quarter [1] - Notable public funds include Dachen Jingheng Mixed A, Guotai Shanghai Stock Exchange Science and Technology Innovation Board Comprehensive ETF, Shanghai Composite Index ETF, Huatai-PineBridge Shanghai Composite Index A, and Dachen Zhuoxiang One-Year Holding Mixed A [1]

Group 1 - The company announced the convening of the fourth board meeting on October 30, 2025, to review the proposal regarding the reversal of asset impairment provisions for the third quarter of 2025 [2] - The amount reversed for asset impairment provisions in the third quarter of 2025 is 25.6518 million yuan [2]

Group 1 - The core viewpoint of the article is that Honglida's financial performance in the first three quarters of 2025 shows a significant decline in revenue and net profit compared to the previous year, indicating potential challenges for the company [1][2]. Group 2 - For the first three quarters of 2025, the company's operating revenue was 475 million yuan, a year-on-year decrease of 31.96% [1]. - The net profit attributable to shareholders was 145 million yuan, down 2.68% year-on-year, while the net profit after deducting non-recurring gains and losses was 107 million yuan, a decrease of 6.50% [1]. - The basic earnings per share for the reporting period was 1.04 yuan [2]. Group 3 - In Q3 2025, the company's gross margin was 55.00%, an increase of 7.68 percentage points year-on-year, but a decrease of 1.17 percentage points quarter-on-quarter [2]. - The net profit margin for Q3 was 50.61%, up 28.36 percentage points year-on-year and 16.47 percentage points quarter-on-quarter [2]. Group 4 - The company's total expenses for the period were 115 million yuan, an increase of 9.54 million yuan compared to the same period last year, with an expense ratio of 24.12%, up 9.08 percentage points year-on-year [2]. - Sales expenses increased by 6.12%, management expenses rose by 19.58%, while R&D expenses decreased by 12.57%, and financial expenses surged by 82.09% year-on-year [2]. Group 5 - As of the end of Q3 2025, the total number of shareholders was 10,800, an increase of 2,759 households, representing a growth of 34.25% [2]. - The average market value of shares held per household increased from 446,300 yuan at the end of the first half to 518,500 yuan, a growth of 16.17% [2]. Group 6 - Honglida is primarily engaged in the research, production, and sales of intelligent equipment for distribution networks, as well as the development and implementation of power application software [3]. - The main business revenue composition includes 98.65% from intelligent distribution network equipment, 0.71% from leasing income, 0.57% from information services, 0.06% from raw material sales, and 0.02% from other products [3]. - The company belongs to the electric power equipment industry, specifically in grid automation equipment, and is associated with concepts such as specialized and innovative enterprises, energy interconnection, smart grids, and power IoT [3].

一、转回资产减值准备情况概述 根据《企业会计准则》以及公司会计政策、会计估计的相关规定，为了真实、 准确地反映公司截至 2025 年 9 月 30 日的财务状况，本着谨慎性原则，公司对截 至 2025 年 9 月 30 日公司及下属子公司的资产进行了减值测试，对公司合并报表 范围内有关资产转回相应的减值准备。2025 年第三季度转回资产减值准备 2,565.18 万元。具体情况如下： 单位：元 | 序号 | 项目 | 年第三季度 2025 转回金额 | 备注 | | --- | --- | --- | --- | | 1 | 信用减值损失 | 25,034,073.29 | 应收票据坏账准备、应收账款坏 账准备、其他应收款坏账准备 | | 2 | 资产减值损失 | 617,680.23 | 存货跌价准备、合同资产减值准 备、其他非流动资产减值准备 | | | 合计 | 25,651,753.52 | - | 二、转回资产减值准备事项的具体说明 （一）信用减值损失 证券代码：688330 证券简称：宏力达 公告编号：2025-042 上海宏力达信息技术股份有限公司 关于 2025 年第三季度转回资产减值准备的公 ...

Group 1 - The core viewpoint of the article highlights that Honglida (SH 688330) reported a significant decline in its third-quarter performance for 2023, with revenue dropping by 31.96% year-on-year to approximately 475 million yuan [1] - The net profit attributable to shareholders decreased by 2.68% year-on-year, amounting to around 145 million yuan [1] - Basic earnings per share fell by 2.26% year-on-year, reaching 1.0441 yuan [1] Group 2 - As of the report, Honglida's market capitalization stands at 5.7 billion yuan [2]